Approval · Notice of Compliance 13294 · 2012
RISEDRONATE: Notice of Compliance 13294
Issued May 25, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13294
- Date
- May 25, 2012
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Bone Metabolism Regulator
- Canadian reference product
- ACTONEL (Procter & Gamble Pharmaceuticals Canada, Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RISEDRONATE | 02352141 | Cancelled Post Market |
Medicinal ingredients
- RISEDRONATE SODIUM HEMI-PENTAHYDRATE 35 MG per TAB